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Over the next decade, a new generation of vaccines will target the neglected 
tropical diseases (NTDs). The goal of most NTD vaccines will be to reduce the 
morbidity and decrease the chronic debilitating nature of these often-forgotten 
infections - outcomes that are hard to measure in the traditional potency-testing 
paradigm. The absence of measurable correlates of protection, a lack of 
permissive animal models for lethal infection, and a lack of clinical indications 
that do not include the induction of sterilizing immunity required us to 
reconsider the traditional bioassay methods for determining vaccine potency. 
Owing to these limitations, potency assay design for NTD vaccines will 
increasingly rely on a paradigm where potency testing is one among many tools 
to ensure that a manufacturing process yields a product of consistent quality. 
This potency test is a bioassay using BALB/c mice, which evaluates the 
immunogenicity of the vaccine at set time interval post manufacture. Herein, we 
discuss the results of 12 month potency testing of Necator americanus-
glutathione-S- transferase-1 (Na-GST-1) vaccine. The Effective Dose 50 (ED50), 
with its 95% fiducial limits (FL) for each time point was determined along with 
the Relative Potency with its 95% FL for 3, 6, 9 and 12 months post manufacture. 
Potency testing has shown that storage at 4° C decreases the ED50 and increases 
the relative potency of Na-GST-1 vaccine. We proposed that the change in ED50 
and relative potency coincide with higher affinity binding of the Na-GST-1 to the 
Alhydrogel® that occurred during storage at 4° C. These preclinical results lay the 
foundation for moving forward with Phase 1 clinical trial in Brazil. 
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The Na-GST-1 vaccine gain potency within the first three months of its 
storage at 4° C and remain immunogenic 12 months post manufacture. 
We proposed that the gain in potency within the first three months 
coincides with the higher affinity binding of the Na-GST-1 to the Alhydrogel® 
that occurred during storage at 4° C. 
The Na-GST-1 vaccine shows increased potency  at each of the tested time 
points compared to its potency at the time of manufacture.  
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Figure 1. Standard Reference Curves  
Figure 2. Cumulative Standard Reference Curves  
Figure 3. Parallelism of linearized standard reference curves  
Figure 4. Global Standard Reference Curve  
Figure 5. Response Threshold (Global Standard Reference Curve)  
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ED50 (µg) 16.49 5.57 6.67 4.22 6.26 
95% Fiducial Limits (µg) (11.72--23.20) (4.09--7.57) (3.63—12.23) (3.06--5.82) (4.74--8.28) 
Relative Potency 1.00 2.84 2.35 3.75 2.49 
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Figure 6. ED50 using probit transformed percent responders  
Figure 7. Relative Potency2  
Standard Reference Serum was generated by vaccinating sixty Balb/c mice with 
0.05µg Na-GST-1 + 80µg Alhydrogel® + 5µg CpG10104  intramuscularly using the 




Necator americanus glutathione-S-transferase-1 (Na-GST-1) is a 24-kDa protein 
from N. americanus that has peroxidase activity and catalyzes the conjugation of 
reduced glutathione to a variety of electrophiles. Na-GST-1 exhibits a high 
affinity for heme in vitro. Because both heme and hematin contain oxidative 
iron, they can generate toxic reactive oxygen species that damage parasite 
structures. Hookworm GSTs may bind and detoxify heme and hematin 
byproducts generated during the blood degradation process. The recombinant 
polypeptide Na-GST-1 was expressed in Pichia pastoris. Na-GST-1 Hookworm 
Vaccine Drug Product was formulated at 0.1 mg/ml of Na-GST-1 with 0.8 mg/ml  
of Alhydrogel®.  The cGMP manufactured vaccine was stored at 4° C.  
Potency testing was performed using Female Balb/c mice. This assay utilizes a 
quantal response or the achievement of a threshold of murine IgG against Na-
GST-1 above which we could assign an individual serum as being ‘positive’. The 
response threshold was obtained using the standard reference serum . We 
developed a standard reference serum (SRS) that we assayed on each ELISA plate 
as a standard reference curve.  
Standard Reference Serum  
Results 
Methods  Results Results Results 
Cumulative curves were obtained from individual time points. Test (ANOVA) of 
parallelism was performed by linearizing these cumulative curves 1. A global 
standard reference curve with the 95% CI was generated using these 
cumulative curves1. A response threshold was estimated using the above global 
curve 1. The Na-GST-1 drug product was fractionated by groups to generate the 
following doses.  
 
 
The above potency animal study was performed at 0, 3, 6, 9 and 12 months 
post manufacturing. The probit transformation of the percentage of responders 
on day 28 in each dose group were plotted against the log10-transformed dose 
of Na-GST-1. ED50 (Effective Dose 50) was obtained using the graphical 
interpolation as well as using the methods described in European 
pharmacopeia2. Similarly, relative potency was calculated using the methods 
described in European pharmacopeia2. Here, the relative potency  compare the 
potency (immunogenicity) of Na-GST-1 vaccine at time 3, 6, 9 and 12 months 
post manufacture to that of its potency at time 0 month (time of release). 
The terminal sera was pooled and stored at -80° C. Four-parameter logistic log 
(4-PL) fit of the standard reference curve data generated by serial dilution of 
standard reference serum on  ELISA plate were plotted on a logistic-log scale. 
The 4-parameter standard reference curves were generated at multiple time 
points.  
Ninety mice were divided into 9 groups. Mice were vaccinated Intra-
peritoneally using the above doses and the following bleed and vaccination 
schedule.  
B = Bleed 
V = Vaccination 
S = Sacrificed 
Table 1. Study Design  
 
Table 2. ED502 and Relative Potency2  
 
A cumulative response threshold of 5AU was estimated using the Global 
Standard Reference Curve (Figure 5).  
ED50 of the Na-GST-1 vaccine was found to be 16.49 µg, 5.57 µg, 6.67 µg, 
4.22 µg and 6.26 µg at 0, 3, 6, 9 and 12 months post manufacture 
respectively (Figure 6, Table 2).  
Relative potency of Na-GST-1 vaccine was found to be  2.84, 2.35, 3.75 
and 2.49 at 3, 6, 9 and 12 months post manufacture respectively (Figure 7, 
Table 2).  
The specification submitted in our IND states, “The criterion for 
acceptance is that the 95% upper fiducial limit of the estimated relative 
potency is not less than 0.5”.  
The upper 95% fiducial limits of the relative potency at 3,6, 9 and 12 
months post manufacture was found to be 4.45, 4.76, 5.98 and 3.75  
respectively. 
